Ian Gaddie
Corneal and Contact Management · Louisville, KYNPI 1053385476
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Tarsus Pharmaceuticals, Inc. at 24.3% of the total.
Across 958 payments — averaging $894.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$208K
- Bausch & Lomb Americas Inc.$183K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$127K
- AbbVie$93K
- Aerie Pharmaceuticals, Inc.$49K
- Harrow Eye, LLC$49K
- plus $147K from 27 others
Across 3 payments — averaging $8840.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aerie Pharmaceuticals, Inc.$27K
What the payments were for
- Consulting fees$273,22632%
- Speaking & faculty fees$467,65555%
- Travel & lodging$85,59610%
- Food & beverage$30,0564%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XDEMVY$178,438
- BIOTRUE$126,294
- VYZULTA$92,816
- ULTRA$77,567
- Rhopressa$51,234
- Rocklatan$49,590
- VEVYE$47,831
- MIEBO$39,109
- LUMIGAN$38,469
- CEQUA$27,555
- XIIDRA$24,008
- COMBIGAN$15,250
- LOTEMAX SM$14,646
- OPD-III$13,500
- BIOTRUE ONE DAY$13,079
- DURYSTA$11,479
- OMNI$11,082
- TRYPTYR$9,405
- ALPHAGAN P$8,664
- Hydrus Microstent$6,500
How this compares
Too few corneal and contact management providers in Kentuckyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 164 | $91,213 |
| XdemvyLotilaner | 43 | $78,918 |
| CombiganBrimonidine Tartrate/Timolol | 72 | $24,422 |
| VyzultaLatanoprostene Bunod | 51 | $20,304 |
| RocklatanNetarsudil Mesylat/Latanoprost | 21 | $18,657 |
| RestasisCyclosporine | 15 | $15,719 |
| RhopressaNetarsudil Mesylate | 14 | $8,087 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 26 | $5,074 |
| Prednisolone Acetate | 29 | $876 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 42 | $819 |
| Latanoprost | 65 | $496 |
| Dorzolamide Hcl | 20 | $362 |
| Timolol Maleate | 19 | $309 |
| Brimonidine Tartrate | 15 | $203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis | $92,605 | $131,354251 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $207,847 | $78,91843 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $49,350 | $26,74435 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $183,053 | $20,30451 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few corneal and contact management providers in Kentuckyon file to place this against a meaningful peer group, so we don't.
Other corneal and contact management in Louisville
- Laura BassettLouisville$6K
- Bruce GaddieLouisville$3K
- Donald GossomLouisville$2K
- Sharon ThompsonLouisville$36
- John MackeyLexington$3K
- Paula Hernandez HooverFrankfort$2K
- Curtis MyersBerea$193
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.